Johnson & Johnson (JNJ +0.3%) unit Janssen Pharmaceutical Companies inks a collaboration agreement with privately held UK biotech Exonate aimed at developing an mRNA-targeted eye drop for retinal vascular diseases such as wet AMD and diabetic macular edema.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.